1
|
Pharmacokinetic Study of Intranasal Dexamethasone and Methylprednisolone Compared with Intravenous Administration: Two Open-Label, Single-Dose, Two-Period, Two-Sequence, Cross-Over Study in Healthy Volunteers. Pharmaceutics 2022; 15:pharmaceutics15010105. [PMID: 36678735 PMCID: PMC9861764 DOI: 10.3390/pharmaceutics15010105] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 11/09/2022] [Accepted: 12/14/2022] [Indexed: 12/30/2022] Open
Abstract
Dexamethasone (DXM) and methylprednisolone (MEP) are potent glucocorticoids used to control several inflammatory conditions. Evidence of delayed DXM reaching the central nervous system (CNS) as well as tachyphylaxis and systemic, undesirable side effects are the main limitations of peripheral delivery. Intranasal administration offers direct access to the brain as it bypasses the blood-brain barrier. The Mucosal Atomization Device is an optimal tool that can achieve rapid absorption into the CNS and the bloodstream across mucosal membranes. This study was designed to evaluate and compare the bioavailability of DXM and MEP after intranasal versus intravenous administration. Two open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover studies were conducted, which involved healthy male and female adult volunteers. After intranasal administration, DXM and MEP were detected in plasma after the first sampling time. Mean peak concentrations of DXM and MEP were 86.61 ng/mL at 60 min and 843.2 ng/mL at 1.5 h post-administration, respectively. DXM and MEP showed high absolute bioavailability, with values of 80% and 95%, respectively. No adverse effects were observed. DXM and MEP systemic bioavailability by intranasal administration was comparable with the intravenous one, suggesting that the intranasal route can be used as a non-invasive and appropriate alternative for systemic drug delivery.
Collapse
|
2
|
Bahr AC, Luz JPDA, Teixeira RB, Türck P, Zimmer A, Castro ALDE, Reis EED, Visioli F, Belló-Klein A, Araujo ASDAR, Schenkel PC. The brief methylprednisolone administration is crucial to mitigate cardiac dysfunction after myocardial infarction. AN ACAD BRAS CIENC 2021; 93:e20210297. [PMID: 34706009 DOI: 10.1590/0001-3765202120210297] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 07/01/2021] [Indexed: 01/24/2023] Open
Abstract
Acute myocardial infarction (AMI) is one of the major causes of heart failure and mortality. Glucocorticoids administration post-infarction has long been proposed, but it has shown conflicting results so far. This controversy may be associated with the glucocorticoid type and the period when it is administered. To elucidate these, the present aims to evaluate if the brief methylprednisolone acetate administration is determinant for heart adaptation after AMI. Male Wistar rats were divided into 3 groups: sham-operated (SHAM); infarcted (AMI); infarcted treated with methylprednisolone acetate (AMI+M). Immediately after surgery, the AMI+M group received a single dose of methylprednisolone acetate (40 mg/kg i.m.). After 56 days, the cardiac function was assessed and lungs, liver and heart were collected to determine rates of hypertrophy and congestion. Heart was used for oxidative stress and metalloproteinase activity analyses. Methylprednisolone acetate attenuated matrix metalloproteinase-2 activity, cardiac dilatation, and prevented the onset of pulmonary congestion, as well as avoided cardiac hypertrophy. Our data indicate that administration of methylprednisolone acetate shortly after AMI may be a therapeutic alternative for attenuation of detrimental ventricular remodeling.
Collapse
Affiliation(s)
- Alan Christhian Bahr
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Julia Paim DA Luz
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Rayane Brinck Teixeira
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Patrick Türck
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Alexsandra Zimmer
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Alexandre Luz DE Castro
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Eduardo Echer Dos Reis
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Fernanda Visioli
- Universidade Federal do Rio Grande do Sul, Departamento de Patologia Oral, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Adriane Belló-Klein
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Alex Sander DA Rosa Araujo
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil
| | - Paulo Cavalheiro Schenkel
- Universidade Federal do Rio Grande do Sul, Departamento de Fisiologia, Instituto de Ciências Básicas da Saúde, R. Sarmento Leite, 500, 90050-170 Porto Alegre, RS, Brazil.,Universidade Federal de Pelotas, Departamento de Fisiologia e Farmacologia, R. Gomes Carneiro, 1, 96010-610 Pelotas, RS, Brazil
| |
Collapse
|
3
|
Hoogevest P, Tiemessen H, Metselaar JM, Drescher S, Fahr A. The Use of Phospholipids to Make Pharmaceutical Form Line Extensions. EUR J LIPID SCI TECH 2021. [DOI: 10.1002/ejlt.202000297] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Peter Hoogevest
- Phospholipid Research Center Im Neuenheimer Feld 515 Heidelberg 69120D‐69120 Germany
| | - Harry Tiemessen
- Technical & Research Development PHAD PDU Specialty Novartis Campus Physical Garden (WSJ 177) 2.14 Basel CH‐4002 Switzerland
| | - Josbert M. Metselaar
- Institute for Experimental Molecular Imaging, RWTH Aachen University Clinic Aachen D‐52074 Germany
- Institute for Biomedical Engineering, Faculty of Medicine RWTH Aachen University Aachen D‐52074 Germany
| | - Simon Drescher
- Phospholipid Research Center Im Neuenheimer Feld 515 Heidelberg D‐69120 Germany
| | - Alfred Fahr
- Professor Emeritus, Pharmaceutical Technology Friedrich‐Schiller‐University Jena Jena Germany
| |
Collapse
|
4
|
Enia G, Catalano C, Misefari V, Salnitro F, Mundo N, Tetta C, Maggiore Q. Complement Activated Leucopenia during Hemodialysis: Effect of Pulse Methyl-prednisolone. Int J Artif Organs 2018. [DOI: 10.1177/039139889001300208] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We tested in vivo the effect of methyl-prednisolone (MP) on C5a release and granulocytopenia occurring early in the course of extracorporeal blood circulation through a Cuprophan dialyzer. MP boluses (30 mg/kg) were given to 10 consenting patients suffering from acute renal failure, immediately before blood started to circulate through a hollow-fiber Cuprophan dialyzer. To avoid drug loss through the dialyzer membrane, dialysate flow was witheld during the first hour of treatment and ultrafiltration was kept near zero (sham dialysis). Control procedures were carried out in a similar way, without MP. MP concentration, differential WBC count and anaphylotoxin C5a were serially measured during the procedures. MP pharmacokinetics was evaluated in six other uremic patients off dialysis. As shown by similar C5a levels in dialyzer effluent blood, complement cascade was activated by Cuprophan to a comparable degree whether or not patients received MP. Neutrophil count dropped 68% during the control procedure and 54% during sham dialysis preceded by MP (95% confidence interval of the difference, 1.97–27.2). Sham dialysis did not apparently influence serum MP levels, as shown by similar peak values in patients undergoing sham dialysis (203 μg/ml ± SEM 33) and in patients off dialysis (177 μg/ml ± 42). In vitro aggregometry showed that the uremic milieu does not interfere with the antiaggregating effect of MP. Our results show that MP at the dosage of 30 mg/kg does not affect complement-mediated granulocytopenia in any important way.
Collapse
Affiliation(s)
- G. Enia
- Centra di Fisiologia Clinica del Consiglio Nazionale delle Ricerche, Reggio Calabria
| | - C. Catalano
- Centra di Fisiologia Clinica del Consiglio Nazionale delle Ricerche, Reggio Calabria
| | - V. Misefari
- Centra di Fisiologia Clinica del Consiglio Nazionale delle Ricerche, Reggio Calabria
| | - F. Salnitro
- Centra di Fisiologia Clinica del Consiglio Nazionale delle Ricerche, Reggio Calabria
| | - N. Mundo
- Centra di Fisiologia Clinica del Consiglio Nazionale delle Ricerche, Reggio Calabria
| | - C. Tetta
- Laboratorio di Immunopatologia, Cattedra di Nefrologia, Ospedale Maggiore S.G. Battista, Molinette, Torino
| | - Q. Maggiore
- Unità Operativa Nefrologia e Dialisi, Ospedale S. Maria Annunziata, Firenze - Italy
| |
Collapse
|
5
|
Matoulková P, Pávek P, Malý J, Vlček J. Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol 2014; 10:425-35. [PMID: 24451000 DOI: 10.1517/17425255.2014.878703] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
INTRODUCTION Due to their multiple effects, glucocorticoids (GCs) have versatile medical uses. They can regulate many xenobiotic-metabolizing enzymes of the cytochrome P450 (CYP) superfamily, and thus, influence pharmacotherapy. AREAS COVERED The aim of this paper is to summarize the molecular effects of GCs on CYP as well as the available clinical evidence on drug-drug interactions (DDIs) between GCs and other drugs in which GCs influence the metabolism of other medicines through modifying CYP activity. We used the factographic database DRUGDEX® along with bibliographic searches. EXPERT OPINION Most of the literature reported CYP3A4 induction by GCs, but this was not proved in all research. As the conclusions on these DDIs are conflicting, there are several issues to be considered like the dosage of GCs, the length of GCs treatment and concomitant therapy, all of which can have an additive inducing effect. Further, in designing a DDI study, crossover studies are preferred. A literature search of the abovementioned information resources provided dissimilar results.
Collapse
Affiliation(s)
- Petra Matoulková
- Charles University in Prague, Faculty of Pharmacy, Department of Social and Clinical Pharmacy , Hradec Kralove , Czech Republic
| | | | | | | |
Collapse
|
6
|
Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis. Int J Pharm 2011; 416:471-7. [PMID: 21440612 DOI: 10.1016/j.ijpharm.2011.03.025] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2010] [Revised: 03/11/2011] [Accepted: 03/11/2011] [Indexed: 11/22/2022]
Abstract
Small-sized (less than 150 nm) long-circulating liposomes (LCL) may be useful as drug-targeting vehicles for anti-inflammatory agents in arthritis, since they selectively home at inflamed joints after i.v. administration. Previously it was shown in experimental arthritis that encapsulation of glucocorticoids (GC) as water-soluble phosphate esters in PEG-liposomes resulted in a strong improvement of the anti-inflammatory effect as compared to the free drug. In the present study, we compared the therapeutic activity and adverse effects induced by 3 different GC encapsulated in LCL in an attempt to further optimize the therapeutic index of liposomal GC in arthritis. Our data showed that with GC (dexamethasone, budesonide) of higher potency than prednisolone, the therapeutic activity of liposomal GC can be increased. However, side effects at the level of body weight and hyperglycemia were noted, related to the sustained free GC level observed after injection of the liposomal GC. An inverse relationship with the clearance rate of the free GC in question was shown. This study stresses the importance of a high clearance rate of the GC to be encapsulated for achieving a maximal therapeutic index with liposomal GC. Therefore high-clearance GC, which until now are only applied in local treatment approaches, may be very useful for the development of novel, highly effective anti-inflammatory preparations for systemic treatment of inflammatory disorders.
Collapse
|
7
|
Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997; 57:401-7. [PMID: 9279965 DOI: 10.3109/00365519709084587] [Citation(s) in RCA: 102] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Phospholipase-A2 has been suggested as having a role in the pathophysiology of acute pancreatitis. The inhibition of phospholipase-A2 was studied in vitro using 17 pharmacological agents in the search for a specific therapy for acute pancreatitis. The inhibitory effect was tested using an isotopic assay system with 2-palmitoyl-(1-14C)-labelled dipalmitoyl phosphatidylcholine as a substrate and 10 microliters of serum from patients with acute necrotizing pancreatitis as an enzyme source. Among all agents tested, anti-inflammatory drugs inhibited enzyme activity most significantly: indomethacin (9.0 x 10(-3) mol l-1) decreased the phospholipase-A2 activity to one- tenth. The weak inhibitory effect could also be demonstrated using a lower concentration of 2 x 10(-5) mol l-1, which can be achieved after intravenous administration of 50 mg of this drug. The other drugs inhibited the enzyme activity at concentrations higher than those achieved after intravenous injections in clinical use. Diclofenac (3.1 x 10(-2) mol l-1) reduced the phospholipase-A2 activity by 93%, ketoprofen (2.0 x 10(-2) mol l-1) or chlorpromazine (1.4 x 10(-2) mol l-1) by 90%, tobramycin (1.7 x 10(-2) mol l-1) by 84%, doxycycline (9.0 x 10(-3) mol l-1) by 61%, dexamethasone (1.7 x 10(-3) mol l-1) by 62%, methylprednisolone (3.8 x 10(-2) mol l-1) by 50%, and pindolol (1.0 x 10(-4) mol l-1) by 59%. A weak inhibition of phospholipase-A2 activity was demonstrated by betamethasone, bupivacaine, digoxin, hydrocortisone, lidocaine, metoprolol, propranolol, and vancomycin. Indomethacin proved the most potent of the tested agents in inhibiting phospholipase-A2 activity in serum from patients with acute pancreatitis and should be further studied in vivo.
Collapse
Affiliation(s)
- A Mäkelä
- Department of Surgery, Helsinki University Central Hospital, Finland
| | | | | |
Collapse
|
8
|
|
9
|
Ferry JJ, Della-Coletta AA, Weber DJ, VanderLugt JT. Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. J Clin Pharmacol 1994; 34:1109-15. [PMID: 7876403 DOI: 10.1002/j.1552-4604.1994.tb01988.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The pharmacokinetics of methylprednisolone were evaluated in 29 healthy volunteers after multiple intravenous doses of methylprednisolone sodium succinate or the novel prodrug, methylprednisolone suleptanate. Subjects were assigned randomly to one of four treatment groups (40, 100, 250, or 500 mg) and then randomly assigned to receive either the sodium succinate or suleptanate prodrugs. Doses were administered every 6 hours for 48 hours. Plasma and urine were assayed for methylprednisolone and unchanged prodrug using HPLC methods. Methylprednisolone pharmacokinetics exhibited both a dose and time dependency, which was similar for administration of both prodrugs. After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester. After multiple dosing, mean clearance values increased from 31.1 to 44.7 L/hr for sodium succinate dosing, and from 31.5 to 46.0 L/hr for suleptanate dosing. Apparent systemic clearance values determined after multiple dosing were 1.5- to 1.8-fold greater than corresponding first-dose values. No dependence on time was apparent for any prodrug pharmacokinetic parameter. These data suggest that the dose dependency of methylprednisolone pharmacokinetics is related to dose-dependent prodrug hydrolysis, whereas the time dependence possibly reflects auto-induction of methylprednisolone metabolism. Based on comparison of methylprednisolone pharmacokinetic parameters derived for each prodrug, methylprednisolone suleptanate resulted in a faster and slightly more efficient conversion to methylprednisolone than methylprednisolone sodium succinate.
Collapse
Affiliation(s)
- J J Ferry
- Department of Clinical Pharmacokinetics, Upjohn Company, Kalamazoo, Michigan 49007
| | | | | | | |
Collapse
|
10
|
Hayball PJ, Cosh DG, Ahern MJ, Schultz DW, Roberts-Thomson PJ. High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. Eur J Clin Pharmacol 1992; 42:85-8. [PMID: 1541321 DOI: 10.1007/bf00314925] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
A commercially available 1.0 g intravenous (i.v.) dosage formulation of methylprednisolone, as the sodium hemisuccinate salt (Solu Medrol, Upjohn) was administered both parenterally and orally (pulse steroid therapy) on separate occasions, to eight elderly (mean 65 y) patients with active rheumatoid arthritis. The relative oral bioavailability of the sterol was 69.2%. Elimination of methylprednisolone was prolonged when given orally; the mean residence times were 7.23 h and 3.94 h for oral and i.v. administrations, respectively. Clinical response to pulse steroid therapy was no different with respect to route of administration. There were no significant differences in standard clinical and laboratory assessments of disease activity when the two therapies were compared. Oral administration of methylprednisolone in patients requiring high-dose pulse steroid therapy is convenient and avoids the discomfort and inconvenience associated with i.v. administration.
Collapse
Affiliation(s)
- P J Hayball
- Pharmacy Department, Repatriation General Hospital, Daw Park, Adelaide, Australia
| | | | | | | | | |
Collapse
|
11
|
|
12
|
Kapisinszky N, Keszthelyi B. High dose intravenous methylprednisolone pulse therapy in patients with rheumatoid arthritis. Ann Rheum Dis 1990; 49:567-8. [PMID: 2383086 PMCID: PMC1004154 DOI: 10.1136/ard.49.7.567] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
13
|
Husberg BS, Konrad PI. The influence of dose interval on the immunosuppressive potency of methylprednisolone: an experimental organ transplant study in isogenous rats. Transpl Int 1990; 3:23-5. [PMID: 2369477 DOI: 10.1007/bf00333198] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Groups of isogenous Brown-Norway rats received heterotopic heart transplants from (Brown-Norway/Wistar Furth) x F1 hybrid rats. Methylprednisolone was administered IV in a daily dose of 5-40 mg/kg, using a dose interval of 24, 12, or 0 h (continuous infusion). Continuous infusion proved to be superior when small daily doses were used and then caused a more than threefold increase in graft survival. High daily doses created a substantial mortality with all dose intervals. Moreover, the equipment used for continuous drug administrations was unreliable beyond 4 weeks of infusion.
Collapse
Affiliation(s)
- B S Husberg
- Transplantation Services, Baylor University Medical Center, Dallas, TX 75246
| | | |
Collapse
|
14
|
Husberg BS, Konrad PI. The influence of dose interval on the immunosuppressive potency of methylprednisolone: an experimental organ transplant study in isogenous rats. Transpl Int 1990. [DOI: 10.1111/j.1432-2277.1990.tb01881.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
15
|
Al-Habet SM, Rogers HJ. Methylprednisolone pharmacokinetics after intravenous and oral administration. Br J Clin Pharmacol 1989; 27:285-90. [PMID: 2655680 PMCID: PMC1379824 DOI: 10.1111/j.1365-2125.1989.tb05366.x] [Citation(s) in RCA: 56] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
1. The pharmacokinetics of methylprednisolone (MP) were studied in five normal subjects following intravenous doses of 20, 40 and 80 mg methylprednisolone sodium succinate (MPSS) and an oral dose of 20 mg methylprednisolone as 4 x 5 mg tablets. Plasma concentrations of MP and MPSS were measured by both high performance thin layer (h.p.t.l.c.) and high pressure liquid chromatography (h.p.l.c.). 2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively. There was no evidence of dose-related changes in these values. The plasma MP concentration-time curves were superimposable when normalized for dose. 3. The bioavailability of methylprednisolone from the 20 mg tablet was 0.82 +/- 0.11 (s.d.). 4. In vivo hydrolysis of MPSS was rapid with a half-life of 4.14 +/- 1.62 (s.d.) min, and was independent of dose. In contrast, in vitro hydrolysis in plasma, whole blood and red blood cells was slow; the process continuing for more than 7 days. Sodium fluoride did not prevent the hydrolysis of MPSS.
Collapse
Affiliation(s)
- S M Al-Habet
- Department of Clinical Pharmacology, Guy's Hospital Medical School University of London
| | | |
Collapse
|
16
|
Möllmann H, Rohdewald P, Barth J, Möllmann C, Verho M, Derendorf H. Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. Pharm Res 1988; 5:509-13. [PMID: 3072558 DOI: 10.1023/a:1015921408870] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The pharmacokinetics of methylprednisolone and two methylprednisolone esters, the phosphate and the hemisuccinate, were investigated after intravenous administration of the esters to 12 healthy male subjects in two different doses (250 and 1000 mg). Methylprednisolone was formed more rapidly from phosphate than from hemisuccinate. During the first 30 min methylprednisolone levels were three to four times higher after phosphate administration than after hemisuccinate. The mean residence time of the hemisuccinate was significantly longer and the total-body clearance lower than those of the phosphate. Whereas very little of the phosphate (mean, 1.7%) was eliminated unchanged into the urine, there were significant amounts of hemisuccinate (mean, 14.7%) excreted renally and therefore not bioavailable. Methylprednisolone saliva levels paralleled plasma levels; the average saliva/plasma ratio was 0.22. Neither phosphate nor hemisuccinate could be detected in saliva. An average of 7.2% of the administered dose was eliminated in the form of methylprednisolone in urine. Renal clearance was 24 ml/min and not dose or prodrug dependent. For both doses endogenous hydrocortisone levels were lowered after 24 hr. For the 1000-mg dose the depression was still significant after 48 hr. The results indicate that methylprednisolone phosphate results in a faster and more efficient conversion to its active form, methylprednisolone, than methylprednisolone hemisuccinate.
Collapse
Affiliation(s)
- H Möllmann
- Medicinal Clinic, University of Bochum, West Germany
| | | | | | | | | | | |
Collapse
|
17
|
Kinetics of regeneration of metronidazole from hemiesters of maleic acid, succinic acid and glutaric acid in aqueous buffer, human plasma and pig liver homogenate. Int J Pharm 1988. [DOI: 10.1016/0378-5173(88)90144-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
18
|
|
19
|
Toutain PL, Koritz GD, Fayolle PM, Alvinerie M. Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. J Pharm Sci 1986; 75:251-5. [PMID: 3517294 DOI: 10.1002/jps.2600750309] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The absolute bioavailability and pharmacokinetic parameters of two methylprednisolone formulations (methylprednisolone sodium succinate and methylprednisolone acetate) were determined in five dogs. Plasma concentrations of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate were measured by sensitive and specific high-performance liquid chromatographic methods. After intravenous methylprednisolone sodium succinate administration, methylprednisolone was released rapidly but the extent of availability was rather low (43.6%). This has been tentatively explained in terms of its subsequent single-pass metabolism in the liver, i.e., hepatic hydrolysis of methylprednisolone sodium succinate followed by immediate hepatic elimination of the released methylprednisolone. After intramuscular administration of methylprednisolone acetate, its absorption was slow (half-time of absorption, 69.04 h) and the availability of the released methylprednisolone was low (42.7%). Therapeutic implications of these results are discussed, especially those which are relevant to shock therapy.
Collapse
|
20
|
Antal EJ, Wright CE, Gillespie WR, Albert KS. Influence of route of administration on the pharmacokinetics of methylprednisolone. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 1983; 11:561-76. [PMID: 6678310 DOI: 10.1007/bf01059057] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
This study was conducted to evaluate the influence of route of administration upon the bioavailability and pharmacokinetics of methylprednisolone sodium succinate. Fourteen healthy adult male volunteers received 40 mg doses of methylprednisolone as the following treatments after an overnight fast in a 4-way crossover design: (a) as a 1 ml i.v. bolus; (b) as a 1 ml i.m. injection; (c) administered as an oral solution; and (d) as 5 X 8 mg oral tablets. Both the ester and free methylprednisolone were determined in plasma and urine. Study results indicate that the ester is rapidly and extensively converted to free methylprednisolone after all routes. The extent of methylprednisolone absorption was equivalent after i.v. and i.m. administration. Both orally administered treatments resulted in a lower extent of absorption attributed to a first-pass effect. Although a slightly lower extent of absorption was demonstrated following the oral administration of the methylprednisolone sodium succinate solution relative to the methylprednisolone oral tablets, this average difference of 9% would probably be of minimal therapeutic importance.
Collapse
|